|
EP2937418B1
(en)
|
2008-10-20 |
2017-10-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin
|
|
CA2839573A1
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
|
US9796974B2
(en)
|
2011-11-18 |
2017-10-24 |
Alnylam Pharmaceuticals, Inc. |
Modified RNAi agents
|
|
DK2872147T3
(da)
|
2012-07-13 |
2023-02-20 |
Wave Life Sciences Ltd |
Fremgangsmåde til fremstilling af kirale oligonukleotider
|
|
TWI664187B
(zh)
|
2013-05-22 |
2019-07-01 |
阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
|
|
IL316808A
(en)
*
|
2014-08-20 |
2025-01-01 |
Alnylam Pharmaceuticals Inc |
Modified double-stranded RNA materials and their uses
|
|
EP3929293A3
(en)
|
2015-04-03 |
2022-03-16 |
University Of Massachusetts |
Fully stabilized asymmetric sirna
|
|
BR112017021053A2
(en)
|
2015-04-13 |
2018-08-14 |
Alnylam Pharmaceuticals, Inc. |
angiopoietin type 3 (angpt13) irna compositions and methods of use thereof
|
|
LT3329002T
(lt)
|
2015-07-31 |
2021-01-11 |
Alnylam Pharmaceuticals, Inc. |
Transtiretino (ttr) irnr kompozicijos ir jų naudojimo būdai, skirti naudoti su ttr susijusių ligų gydymui arba prevencijai
|
|
WO2017030973A1
(en)
|
2015-08-14 |
2017-02-23 |
University Of Massachusetts |
Bioactive conjugates for oligonucleotide delivery
|
|
WO2017132669A1
(en)
|
2016-01-31 |
2017-08-03 |
University Of Massachusetts |
Branched oligonucleotides
|
|
CN115721729A
(zh)
*
|
2016-02-01 |
2023-03-03 |
阿拉基斯医疗公司 |
治疗rna介导的疾病的化合物和方法
|
|
US10876121B2
(en)
|
2016-04-01 |
2020-12-29 |
Avidity Biosciences, Inc. |
EGFR nucleic acids and uses thereof
|
|
WO2017173297A1
(en)
|
2016-04-01 |
2017-10-05 |
Avidity Biosciences Llc |
Beta-catenin nucleic acids and uses thereof
|
|
KR102775461B1
(ko)
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
US10858656B2
(en)
|
2016-04-01 |
2020-12-08 |
Avidity Biosciences, Inc. |
KRAS nucleic acids and uses thereof
|
|
TWI912633B
(zh)
|
2016-06-06 |
2026-01-21 |
美商愛羅海德製藥公司 |
5'-環-磷酸修飾之核苷酸
|
|
WO2018031933A2
(en)
|
2016-08-12 |
2018-02-15 |
University Of Massachusetts |
Conjugated oligonucleotides
|
|
WO2018035380A1
(en)
*
|
2016-08-17 |
2018-02-22 |
Solstice Biologics, Ltd. |
Polynucleotide constructs
|
|
CN110325540A
(zh)
*
|
2016-11-07 |
2019-10-11 |
纳诺索尔公司 |
转录后化学修饰的双链rna
|
|
US11447519B2
(en)
|
2016-11-10 |
2022-09-20 |
San Diego State University Research Foundation |
Compounds for fluorescence sensing of duplex formation
|
|
WO2018098328A1
(en)
*
|
2016-11-23 |
2018-05-31 |
Alnylam Pharmaceuticals, Inc. |
Modified rna agents with reduced off-target effect
|
|
TW202313978A
(zh)
*
|
2016-11-23 |
2023-04-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
|
|
WO2018111978A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
|
KR102568559B1
(ko)
|
2016-12-14 |
2023-08-18 |
얀센 바이오테크 인코포레이티드 |
Cd8a-결합 섬유결합소 iii형 도메인
|
|
TWI865997B
(zh)
*
|
2016-12-16 |
2024-12-11 |
美商阿尼拉製藥公司 |
使用甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物於治療或預防ＴＴＲ相關疾病之方法
|
|
EP3550022A1
(en)
*
|
2018-04-05 |
2019-10-09 |
Silence Therapeutics GmbH |
Products and compositions
|
|
US11015198B2
(en)
*
|
2017-04-05 |
2021-05-25 |
Silence Therapeutics Gmbh |
Products and compositions
|
|
EP4219714A3
(en)
*
|
2017-04-05 |
2023-08-30 |
Silence Therapeutics GmbH |
Rna interference mediated inhibition of tmprss6
|
|
WO2018237245A1
(en)
|
2017-06-23 |
2018-12-27 |
University Of Massachusetts |
TWO TAIL SELF-ADMINISTRATION SIRNA AND ASSOCIATED METHODS
|
|
US11597744B2
(en)
|
2017-06-30 |
2023-03-07 |
Sirius Therapeutics, Inc. |
Chiral phosphoramidite auxiliaries and methods of their use
|
|
MX2020001912A
(es)
|
2017-09-14 |
2020-03-24 |
Arrowhead Pharmaceuticals Inc |
Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso.
|
|
EP3684931A1
(en)
|
2017-09-19 |
2020-07-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
|
|
SG11202003126VA
(en)
*
|
2017-10-04 |
2020-05-28 |
Avidity Biosciences Inc |
Nucleic acid-polypeptide compositions and uses thereof
|
|
SG11202003082UA
(en)
*
|
2017-11-13 |
2020-05-28 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
|
|
MX2020003695A
(es)
|
2017-11-30 |
2020-08-03 |
Arrakis Therapeutics Inc |
Fotosondas de union a acido nucleico y usos de las mismas.
|
|
CN118291456A
(zh)
*
|
2017-12-01 |
2024-07-05 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN110944675B9
(zh)
*
|
2017-12-01 |
2024-08-09 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
WO2019105403A1
(zh)
*
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
WO2019105414A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
JP7360716B2
(ja)
|
2017-12-01 |
2023-10-13 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
|
|
CN111050807B
(zh)
*
|
2017-12-01 |
2024-05-28 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
HRP20250277T1
(hr)
|
2017-12-01 |
2025-05-09 |
Suzhou Ribo Life Science Co., Ltd. |
Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba
|
|
CN118638787A
(zh)
|
2017-12-06 |
2024-09-13 |
艾维迪提生物科学公司 |
治疗肌萎缩和强直性肌营养不良的组合物和方法
|
|
JP7348185B2
(ja)
*
|
2017-12-21 |
2023-09-20 |
アルニラム ファーマスーティカルズ インコーポレイテッド |
キラル富化二本鎖ｒｎａ剤
|
|
EP3677588A4
(en)
*
|
2017-12-26 |
2020-11-25 |
Guangzhou Ribobio Co., Ltd. |
MODIFIED OLIGONUCLEOTIDES AND COMPOUND WHICH CAN BE USED FOR THE SYNTHESIS OF THEM
|
|
CN110959011B
(zh)
|
2017-12-29 |
2023-03-28 |
苏州瑞博生物技术股份有限公司 |
缀合物及其制备方法和用途
|
|
EP3740248A4
(en)
*
|
2018-03-02 |
2022-01-26 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for treating bile duct paucity-associated conditions
|
|
US20210155926A1
(en)
*
|
2018-04-05 |
2021-05-27 |
Silence Therapeutics Gmbh |
siRNAs WITH AT LEAST TWO LIGANDS AT DIFFERENT ENDS
|
|
US11560563B2
(en)
|
2018-04-05 |
2023-01-24 |
Silence Therapeutics Gmbh |
SiRNAs with vinylphosphonate at the 5′ end of the antisense strand
|
|
WO2019217397A2
(en)
*
|
2018-05-07 |
2019-11-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for improving strand biased
|
|
CA3098623A1
(en)
|
2018-05-07 |
2019-11-14 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
|
EP3802827A4
(en)
*
|
2018-05-16 |
2022-08-03 |
Alnylam Pharmaceuticals, Inc. |
MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT
|
|
BR112021002440A2
(pt)
|
2018-08-10 |
2021-05-04 |
University Of Massachusetts |
oligonucleotídeos modificados visando snps
|
|
WO2020038377A1
(zh)
|
2018-08-21 |
2020-02-27 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的药物组合物和缀合物及其用途
|
|
WO2020041769A1
(en)
*
|
2018-08-23 |
2020-02-27 |
University Of Massachusetts |
O-methyl rich fully stabilized oligonucleotides
|
|
CA3114396A1
(en)
*
|
2018-09-28 |
2020-04-02 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
JP7376952B2
(ja)
|
2018-09-30 |
2023-11-09 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
ｓｉＲＮＡ複合体及びその調製方法と使用
|
|
US12600965B2
(en)
*
|
2018-11-09 |
2026-04-14 |
Alnylam Pharmaceuticals, Inc. |
Modified double stranded oligonucleotide
|
|
HUE068630T2
(hu)
|
2018-12-10 |
2025-01-28 |
Amgen Inc |
Mutáns PiggyBac transzpozáz
|
|
SG11202105900UA
(en)
*
|
2018-12-10 |
2021-07-29 |
Amgen Inc |
CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF
|
|
AU2019405783B2
(en)
*
|
2018-12-19 |
2026-03-26 |
Alnylam Pharmaceuticals, Inc. |
Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof
|
|
PT4285929T
(pt)
|
2018-12-20 |
2026-01-02 |
Humabs Biomed Sa |
Terapêutica de combinação contra o vhb
|
|
CN112423795B
(zh)
*
|
2018-12-28 |
2026-06-26 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN111378658B
(zh)
*
|
2018-12-28 |
2024-03-15 |
苏州瑞博生物技术股份有限公司 |
抑制TIMP-1基因表达的siRNA、含有该siRNA的药物组合物及其用途
|
|
JP7507495B2
(ja)
*
|
2018-12-28 |
2024-06-28 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
CN111378655B
(zh)
*
|
2018-12-28 |
2024-03-19 |
苏州瑞博生物技术股份有限公司 |
抑制CTGF基因表达的siRNA、含有该siRNA的药物组合物及其用途
|
|
CN111378657B
(zh)
*
|
2018-12-28 |
2024-03-15 |
苏州瑞博生物技术股份有限公司 |
抑制COL1A1基因表达的siRNA、含有该siRNA的药物组合物及其用途
|
|
CN111378659B
(zh)
*
|
2018-12-29 |
2024-01-30 |
苏州瑞博生物技术股份有限公司 |
抑制stat3基因表达的核酸、含有该核酸的药物组合物及其用途
|
|
CN113330117B
(zh)
*
|
2019-01-18 |
2024-05-28 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN113614232A
(zh)
|
2019-01-18 |
2021-11-05 |
马萨诸塞大学 |
动态药代动力学修饰锚
|
|
AU2020252020A1
(en)
*
|
2019-03-29 |
2021-11-11 |
University Of Massachusetts |
Oligonucleotide-based modulation of C90RF72
|
|
EP3966328A4
(en)
|
2019-05-06 |
2023-10-18 |
University Of Massachusetts |
Anti-c9orf72 oligonucleotides and related methods
|
|
WO2020232024A1
(en)
*
|
2019-05-13 |
2020-11-19 |
Vir Biotechnology, Inc. |
Compositions and methods for treating hepatitis b virus (hbv) infection
|
|
WO2020236600A1
(en)
*
|
2019-05-17 |
2020-11-26 |
Alnylam Pharmaceuticals, Inc. |
Oral delivery of oligonucleotides
|
|
CN113286888B
(zh)
*
|
2019-05-22 |
2023-12-22 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
JP7610848B2
(ja)
|
2019-05-22 |
2025-01-09 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、薬物組成物及び複合体ならびに調製方法と使用
|
|
CN113227376B
(zh)
*
|
2019-05-22 |
2024-04-09 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
CN111973619B
(zh)
*
|
2019-05-23 |
2024-01-30 |
苏州瑞博生物技术股份有限公司 |
核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
|
|
CN113795582B
(zh)
|
2019-05-24 |
2024-05-24 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
CN113891939B
(zh)
*
|
2019-05-24 |
2024-04-02 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
CN113795280B
(zh)
*
|
2019-05-24 |
2024-04-05 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
SG11202113112WA
(en)
*
|
2019-05-30 |
2021-12-30 |
Amgen Inc |
Rnai constructs for inhibiting scap expression and methods of use thereof
|
|
CN112007040B
(zh)
*
|
2019-05-31 |
2024-01-30 |
苏州瑞博生物技术股份有限公司 |
用于治疗乙型病毒性肝炎的联合用药物
|
|
JP7581252B2
(ja)
|
2019-06-06 |
2024-11-12 |
アビディティー バイオサイエンシーズ，インク． |
Ｕｎａアミダイトおよびその使用
|
|
WO2020247782A1
(en)
|
2019-06-06 |
2020-12-10 |
Avidity Biosciences, Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
|
JP7785543B2
(ja)
*
|
2019-06-21 |
2025-12-15 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
構造的に明確なｓｉＲＮＡ－二重可変ドメイン免疫グロブリンコンジュゲート
|
|
KR20220047989A
(ko)
|
2019-08-09 |
2022-04-19 |
유니버시티 오브 매사추세츠 |
Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
|
|
KR20220062517A
(ko)
|
2019-08-15 |
2022-05-17 |
아이오니스 파마수티컬즈, 인코포레이티드 |
결합 변형된 올리고머 화합물 및 이의 용도
|
|
US12365894B2
(en)
|
2019-09-16 |
2025-07-22 |
University Of Massachusetts |
Branched lipid conjugates of siRNA for specific tissue delivery
|
|
US11781138B2
(en)
|
2019-10-14 |
2023-10-10 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
|
CN114786682B
(zh)
|
2019-10-14 |
2024-07-16 |
Aro生物疗法公司 |
结合cd71的纤维粘连蛋白iii型结构域
|
|
WO2021076543A1
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Epcam binding fibronectin type iii domains
|
|
EP4055165A1
(en)
*
|
2019-11-06 |
2022-09-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
WO2021092371A2
(en)
*
|
2019-11-06 |
2021-05-14 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
|
CN112876534B
(zh)
*
|
2019-11-29 |
2024-02-09 |
苏州瑞博生物技术股份有限公司 |
肝靶向化合物及缀合物
|
|
AU2021232029A1
(en)
*
|
2020-03-06 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of transthyretin (TTR)
|
|
TW202144572A
(zh)
|
2020-03-19 |
2021-12-01 |
美商亞維代堤生物科學公司 |
治療臉肩胛肱骨肌肉失養症之組合物及方法
|
|
KR102927945B1
(ko)
|
2020-03-27 |
2026-02-23 |
어비디티 바이오사이언시스 인크. |
근이영양증의 치료용 조성물 및 방법
|
|
JP2023521604A
(ja)
*
|
2020-03-30 |
2023-05-25 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
微小管関連タンパク質タウ（ＭＡＰＴ）ｉＲＮＡ剤組成物およびその使用方法
|
|
CN115698288A
(zh)
*
|
2020-04-08 |
2023-02-03 |
北京瑞博开拓医药科技有限公司 |
核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
|
|
CA3174079A1
(en)
|
2020-05-26 |
2021-12-02 |
Anastasia Khvorova |
Synthetic oligonucleotides having regions of block and cluster modifications
|
|
US20230340485A1
(en)
*
|
2020-06-16 |
2023-10-26 |
Alnylam Pharmaceuticals, Inc. |
ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
US20230257745A1
(en)
|
2020-07-10 |
2023-08-17 |
Alnylam Pharmaceuticals, Inc. |
Circular siRNAs
|
|
CN116209762A
(zh)
*
|
2020-07-30 |
2023-06-02 |
阿达尔克斯制药有限公司 |
Adar依赖性编辑组合物及其使用方法
|
|
US12329828B2
(en)
|
2020-09-16 |
2025-06-17 |
San Diego State University (Sdsu) Foundation |
Pyrimidine nucleoside compounds for fluorescence imaging and spectroscopy
|
|
CN116333013B
(zh)
*
|
2020-09-30 |
2025-09-02 |
纳肽得(青岛)生物医药有限公司 |
一种靶向配体
|
|
CR20230308A
(es)
|
2020-12-11 |
2023-09-08 |
Civi Biopharma Inc |
Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
|
|
CN114685585B
(zh)
*
|
2020-12-31 |
2024-06-04 |
苏州瑞博生物技术股份有限公司 |
核苷酸序列、双链寡核苷酸、药物组合物与缀合物及制备方法和用途
|
|
US20240116973A1
(en)
*
|
2021-01-15 |
2024-04-11 |
Alnylam Pharmaceuticals, Inc. |
Modified oligonucleotides
|
|
CN116761616A
(zh)
*
|
2021-01-22 |
2023-09-15 |
阿耐拉姆制药公司 |
经修饰的双链寡核苷酸
|
|
EP4291654A2
(en)
|
2021-02-12 |
2023-12-20 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
|
BR112023017737A2
(pt)
|
2021-03-04 |
2023-10-03 |
Alnylam Pharmaceuticals Inc |
Composições de irna de angiopoietina-semelhantes 3 (angptl3) e métodos de uso das mesmas
|
|
WO2022189861A1
(en)
|
2021-03-08 |
2022-09-15 |
Tollys |
Carbohydrate conjugates of tlr3 ligands and uses thereof
|
|
BR112023019981A2
(pt)
|
2021-03-29 |
2023-12-12 |
Alnylam Pharmaceuticals Inc |
Composições do agente irna de huntingtina (htt) e métodos de uso das mesmas
|
|
JP2024517610A
(ja)
|
2021-04-14 |
2024-04-23 |
アロ・バイオセラピューティクス・カンパニー |
Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン
|
|
KR20240031947A
(ko)
|
2021-04-14 |
2024-03-08 |
에이알오 바이오테라퓨틱스 컴패니 |
Fn3 도메인-시르나 접합체 및 이의 용도
|
|
IL309334A
(en)
|
2021-06-23 |
2024-02-01 |
Univ Massachusetts |
Anti-FLT1 optimized oligonucleotide compounds for the treatment of preeclampsia and other angiogenic disorders
|
|
US12612626B2
(en)
*
|
2021-06-24 |
2026-04-28 |
Sirnaomics, Inc. |
siRNA compound that inhibits expression of APOC3
|
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
|
IL309897A
(en)
|
2021-07-21 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Target gene IRNA compositions associated with a metabolic disorder and methods of using them
|
|
CN115819484B
(zh)
*
|
2021-07-23 |
2026-06-02 |
苏州瑞博生物技术股份有限公司 |
双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
|
|
AR126675A1
(es)
*
|
2021-08-03 |
2023-11-01 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE ARNi CONTRA LA TRANSTIRRETINA (TTR) Y SUS MÉTODOS DE USO
|
|
EP4401792A4
(en)
|
2021-09-16 |
2025-12-03 |
Avidity Biosciences Inc |
COMPOSITIONS AND METHODS OF TREATMENT OF FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY
|
|
KR20240067943A
(ko)
|
2021-09-24 |
2024-05-17 |
알닐람 파마슈티칼스 인코포레이티드 |
미소관 연관 단백질 타우(MAPT) iRNA 제제 조성물 및 이의 사용 방법
|
|
EP4416284A1
(en)
|
2021-10-15 |
2024-08-21 |
Alnylam Pharmaceuticals, Inc. |
Extra-hepatic delivery irna compositions and methods of use thereof
|
|
WO2023069495A1
(en)
*
|
2021-10-19 |
2023-04-27 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides with 2'-deoxy-2'-f-2'-c-methyl nucleotides
|
|
KR20240103025A9
(ko)
|
2021-11-16 |
2025-12-10 |
상하이 아르고 바이오파마슈티칼 씨오., 엘티디. |
안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법
|
|
WO2023109932A1
(zh)
*
|
2021-12-16 |
2023-06-22 |
上海拓界生物医药科技有限公司 |
一种dsRNA、其制备方法及应用
|
|
CN119320418A
(zh)
*
|
2022-01-05 |
2025-01-17 |
大睿生物医药科技(上海)有限公司 |
具有核苷酸类似物的双链rna
|
|
EP4495241A1
(en)
|
2022-03-16 |
2025-01-22 |
Daiichi Sankyo Company, Limited |
Chemically-modified oligonucleotide having rnai activity
|
|
IL315659A
(en)
|
2022-03-16 |
2024-11-01 |
Daiichi Sankyo Co Ltd |
siRNA FOR SUPPRESSING EXPRESSION OF TRANSFERRIN RECEPTOR-2
|
|
IL315546A
(en)
|
2022-03-16 |
2024-11-01 |
Empirico Inc |
GALNAC compositions to improve siRNA bioavailability
|
|
EP4499834A2
(en)
|
2022-03-28 |
2025-02-05 |
Empirico Inc. |
Modified oligonucleotides
|
|
EP4532724A4
(en)
*
|
2022-06-02 |
2026-06-24 |
Ionis Pharmaceuticals Inc |
LINKED MODIFIED OLIGOMER COMPOUNDS AND THEIR USES
|
|
EP4598544A1
(en)
*
|
2022-10-07 |
2025-08-13 |
Alnylam Pharmaceuticals, Inc. |
Plasminogen (plg) irna compositions and methods of use thereof
|
|
TW202430637A
(zh)
|
2022-11-16 |
2024-08-01 |
美商戴瑟納製藥股份有限公司 |
Stat3靶向性寡核苷酸及其用途
|
|
CN121294438A
(zh)
|
2022-12-19 |
2026-01-09 |
昂拓生物医药有限公司 |
高级rna靶向(arnatar)
|
|
WO2024153166A1
(zh)
|
2023-01-20 |
2024-07-25 |
石药集团中奇制药技术（石家庄）有限公司 |
一种经修饰的核苷单体及双链核糖核酸
|
|
WO2024175586A2
(en)
|
2023-02-21 |
2024-08-29 |
Vib Vzw |
Inhibitors of synaptogyrin-3 expression
|
|
WO2024175588A1
(en)
|
2023-02-21 |
2024-08-29 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
|
IL323663A
(en)
|
2023-04-06 |
2025-11-01 |
Shanghai Argo Biopharmaceutical Co Ltd |
Nucleoside analog for 5'-phosphonate modification and oligonucleotide prepared therefrom
|
|
WO2024229377A1
(en)
*
|
2023-05-03 |
2024-11-07 |
Ionis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides and uses thereof
|
|
TW202508607A
(zh)
*
|
2023-05-19 |
2025-03-01 |
大陸商北京炫景瑞醫藥科技有限公司 |
雙股寡核苷酸及其共軛物和用途
|
|
JP2026520610A
(ja)
|
2023-06-13 |
2026-06-23 |
アーナター セラピューティクス インコーポレイテッド |
アンジオテンシノーゲンのための高度ｒｎａ標的化技術（ａｒｎａｔａｒ）
|
|
WO2024263883A2
(en)
*
|
2023-06-22 |
2024-12-26 |
The University Of North Carolina At Chapel Hill |
5' antisense dna modifications to enhance rna interference activity
|
|
US12491257B2
(en)
|
2023-06-27 |
2025-12-09 |
Avidity Biosciences, Inc. |
Compositions and methods of using PRKAG2-targeting antibody-oligonucleotide conjugates
|
|
AU2024308906A1
(en)
|
2023-06-30 |
2026-02-05 |
Atrium Therapeutics, Inc. |
Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates
|
|
CN118063533B
(zh)
*
|
2023-09-18 |
2024-08-27 |
广州必贝特医药股份有限公司 |
修饰的核苷酸化合物、其寡聚核苷酸及其应用
|
|
WO2025064660A2
(en)
|
2023-09-21 |
2025-03-27 |
Alnylam Pharmaceuticals, Inc. |
Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
|
|
CN117534717A
(zh)
*
|
2024-01-09 |
2024-02-09 |
凯莱英生命科学技术(天津)有限公司 |
5′-(e)-乙烯基磷酸酯的合成方法
|
|
WO2025165891A1
(en)
|
2024-01-29 |
2025-08-07 |
Arnatar Therapeutics, Inc |
Translation enhancing nucleic acid compounds: aso coupled translation - upregulation 1 (act-up1) and uses thereof
|
|
WO2025196505A2
(en)
|
2024-03-22 |
2025-09-25 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for inhibiting cytochrome p450 family 7 subfamily a member 1 (cyp7a1) expression
|
|
WO2026041784A1
(en)
|
2024-08-23 |
2026-02-26 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|
|
WO2026054553A1
(ko)
*
|
2024-09-06 |
2026-03-12 |
올릭스 주식회사 |
선천성 면역 반응 기반 항암 요법을 위한 이중 가닥 rna 및 이의 용도
|
|
WO2026052079A1
(zh)
*
|
2024-09-07 |
2026-03-12 |
苏州瑞博生物技术股份有限公司 |
寡核苷酸、寡核苷酸缀合物及组合物和用途
|
|
WO2026052078A1
(zh)
*
|
2024-09-07 |
2026-03-12 |
苏州瑞博生物技术股份有限公司 |
寡核苷酸、寡核苷酸缀合物及组合物和用途
|
|
WO2026052088A1
(zh)
*
|
2024-09-07 |
2026-03-12 |
北京瑞博开拓医药科技有限公司 |
寡核苷酸、寡核苷酸缀合物及组合物和用途
|
|
WO2026052084A1
(zh)
*
|
2024-09-07 |
2026-03-12 |
苏州瑞博生物技术股份有限公司 |
寡核苷酸、寡核苷酸缀合物及组合物和用途
|
|
WO2026109697A1
(en)
*
|
2024-11-22 |
2026-05-28 |
Ribocure Pharmaceuticals Ab |
Oligonucleotide, oligonucleotide conjugate and composition and use thereof
|
|
WO2026131490A1
(en)
*
|
2024-12-20 |
2026-06-25 |
Ribocure Pharmaceuticals Ab |
Oligonucleotide, oligonucleotide conjugate and composition, and use thereof
|
|
WO2026158295A1
(zh)
*
|
2025-01-21 |
2026-07-30 |
成都倍特锐玛生物医药科技有限公司 |
靶向hbv的小核酸
|